Stocks in Play: Profound Medical Corp.
Tuesday, April 29, 2025
10:22 AM EST - Profound Medical Corp. : Announced initial perioperative data from the Level 1 post-market CAPTAIN trial comparing the safety and efficacy of the TULSA procedure with radical prostatectomy in men with organ-confined, intermediate-risk, Gleason Score 7 (Grade Group 2 and 3) prostate cancer. Profound Medical Corp. (T.PRN) shares were up $0.10 at 6.66.Stocks in Play: Profound Medical Corp. , Tue, 29 Apr 2025 10:57:06 EST
